Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

11 terminated/withdrawn out of 99 trials

Success Rate

71.1%

-15.4% vs industry average

Late-Stage Pipeline

10%

10 trials in Phase 3/4

Results Transparency

0 of 27 completed trials have results

Key Signals

19 recruiting9 terminated

Enrollment Performance

Analytics

Phase 2

36(45.0%)

N/A

33(41.3%)

Phase 3

5(6.3%)

Phase 4

5(6.3%)

Phase 1

1(1.3%)

80Total

Phase 2(36)

N/A(33)

Phase 3(5)

Phase 4(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (99)

Showing 20 of 99 trials

NCT06638931Phase 2Recruiting

Agnostic Therapy in Rare Solid Tumors

Role: lead

NCT07463092Not ApplicableRecruiting

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

Role: collaborator

NCT05622136Phase 2Active Not Recruiting

Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma

Role: lead

NCT06435286Phase 2Recruiting

Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States

Role: collaborator

NCT07432360Recruiting

Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology

Role: collaborator

NCT07376317Phase 2Active Not Recruiting

Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)

Role: lead

NCT07316686Phase 1Not Yet Recruiting

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Role: lead

NCT06640283Phase 2Recruiting

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

Role: lead

NCT05354778Not ApplicableRecruiting

HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study

Role: collaborator

NCT07066046Not ApplicableRecruiting

Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions

Role: lead

NCT06978673Not ApplicableNot Yet Recruiting

Neurolytic Block Techniques In Abdominal Visceral Cancer Pain

Role: lead

NCT06982274Phase 2Recruiting

Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia

Role: lead

NCT06988865Completed

Benign Migratory Glossitis Associated With Antiangiogenic Drugs

Role: lead

NCT06034561Phase 2Recruiting

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

Role: lead

NCT05959720Recruiting

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Role: lead

NCT06077981Not ApplicableRecruiting

Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections

Role: lead

NCT06070376Not ApplicableRecruiting

Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.

Role: lead

NCT04522570Not ApplicableActive Not Recruiting

Thermal Ablation of Cervical Metastases From Thyroid Carcinoma

Role: lead

NCT06887621Phase 2Recruiting

Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery

Role: lead

NCT02185443Phase 2Recruiting

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases

Role: collaborator